Porous graphitic carbon based chromatography hyphenated with mass spectrometry: A new strategy for profiling thiopurine nucleotides in patients with inflammatory bowel diseases.

Azathioprine Inflammatory bowel diseases Mass spectrometry Porous graphitic carbon based chromatography Therapeutic drug monitoring Thiopurine nucleotides

Journal

Analytica chimica acta
ISSN: 1873-4324
Titre abrégé: Anal Chim Acta
Pays: Netherlands
ID NLM: 0370534

Informations de publication

Date de publication:
15 Nov 2020
Historique:
received: 03 07 2020
revised: 19 08 2020
accepted: 29 08 2020
entrez: 6 11 2020
pubmed: 7 11 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Thiopurine (TP) treatment is discontinued in up to 30% of patients suffering from inflammatory bowel diseases (IBD) due to various adverse effects. Therapeutic drug monitoring of biologically active TP metabolites, i.e. thiopurine nucleotides (TPN), can help to optimize the efficacy and safety of the TP treatment. In our work, a novel strategy for TPN profiling, based on a porous graphitic carbon (PGC) chromatography, was developed. The validated PGC-MS method was compared with ion-exchange LC-MS, a currently leading analytical approach established for the determination of TPN. The innovative approach enabled an enhancement of several key performance parameters demanded in a clinical routine use, namely (i) selectivity (time- and mass-recognition of all 12 TPN in one run), (ii) sensitivity (2-5-fold increase in intensities of the analytical signals), (iii) sample throughput (25% shorter analysis time). Application of the novel TPN profiling strategy to a pilot clinical study (12 patients) revealed significantly higher levels of 6-methylthioguanine 5'-diphosphate (MeTGDP) in non-responsive IDB patients treated with azathioprine. Some other TPN are very close to the critical level (p = 0.05) and they will need larger groups of IBD patients to confirm definitively their relevance. In conclusion, the developed PGC-MS method represents a significant improvement to currently available methods for detailed profiling of TPN and its use in bigger clinical studies should lead to a better understanding of the relationship between TPN profiles and therapeutic outcome.

Identifiants

pubmed: 33153610
pii: S0003-2670(20)30911-9
doi: 10.1016/j.aca.2020.08.064
pii:
doi:

Substances chimiques

Nucleotides 0
Carbon 7440-44-0
Graphite 7782-42-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-73

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Daniel Pecher (D)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic; Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic. Electronic address: pecher1@uniba.sk.

Zuzana Zelinkova (Z)

Department of Gastroenterology, St Michael's Hospital, Satinskeho 1, SK-811 08, Bratislava, Slovak Republic. Electronic address: zuzana.zelinkova@nsmas.sk.

Jana Lucenicova (J)

Department of Biochemistry & Hematology, St Michael's Hospital, Satinskeho 1, SK-811 08, Bratislava, Slovak Republic. Electronic address: jana.lucenicova@nsmas.sk.

Maikel Peppelenbosch (M)

Gastrolab, Erasmus Medical Center, Wytemaweg 80, 3015, CN Rotterdam, the Netherlands. Electronic address: m.peppelenbosch@erasmusmc.nl.

Svetlana Dokupilova (S)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic; Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic. Electronic address: dokupilova@fpharm.uniba.sk.

Veronika Mikusova (V)

Department of Galenic Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic. Electronic address: janosova@fpharm.uniba.sk.

Peter Mikus (P)

Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic; Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32, Bratislava, Slovak Republic. Electronic address: mikus@fpharm.uniba.sk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH